KAMADA LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,909 ILa | +1.33% |
|
-1.55% | -14.28% |
| Mar. 06 | Transcript : Kamada Ltd., Q4 2023 Earnings Call, Mar 06, 2024 | |
| Mar. 06 | Kamada Ltd. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Kamada Ltd is Israel based company, focused on plasma-derived protein therapeutics with a commercial product portfolio and a late-stage product pipeline. The Company uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived Immune globulins.
Sector
Pharmaceuticals
Calendar
2024-05-13
- Q1 2024 Earnings Release (Projected)
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -14.28% | 289M | |
| -6.02% | 84.46B | |
| +3.95% | 40.85B | |
| -26.37% | 27.69B | |
| +52.09% | 24.28B | |
| -6.59% | 17.09B | |
| -32.37% | 13.67B | |
| -10.45% | 11.79B | |
| -15.88% | 11.86B | |
| -2.85% | 8.07B |
- Stock Market
- Equities
- KMDA Stock
- News Kamada Ltd.
- Kamada : Amends GLASSIA License Contract with Takeda
